OS Therapies Provides First Half 2026 Corporate Outlook [Yahoo! Finance]
OS Therapies Incorporated (OSTX)
Company Research
Source: Yahoo! Finance
or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma (Metastatic Osteosarcoma Program) under Accelerated Approval Program Biomarker data from Phase 2b Metastatic Osteosarcoma Program human clinical trial expected to be released during week of J.P. Morgan Healthcare Conference 2026 UK and EU Marketing Authorisation Application (MAA) submissions for conditional approval expected by end of February 2026 and March 2026, respectively Company expects to participate in multiple H1 2026 meetings with U.S. FDA, U.K. MHRA and Europe's EMA as part of processes to gain regulatory approvals OS Animal Health 'go-public' transaction SEC filing expected in early January 2026 Delayed data from OST-504 Phase 1 trial in castration resistant prostate cancer expected in Q1 2026 after prioritizing biomarker lab partner resources for osteosarcoma data analysis, with End of Phase 1 FDA meeting expected in Q2 2026 Company plans to request End of Phase 2 meeting with FDA to revi
Show less
Read more
Impact Snapshot
Event Time:
OSTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OSTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OSTX alerts
High impacting OS Therapies Incorporated news events
Weekly update
A roundup of the hottest topics
OSTX
News
- OS Therapies Enters into Warrant Inducement Agreements [Yahoo! Finance]Yahoo! Finance
- OS Therapies provides first half 2026 corporate outlook [Seeking Alpha]Seeking Alpha
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)PR Newswire
- OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma [Yahoo! Finance]Yahoo! Finance
- Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 [Yahoo! Finance]Yahoo! Finance
OSTX
Earnings
- 11/17/25 - Miss
OSTX
Sec Filings
- 1/12/26 - Form 8-K
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- OSTX's page on the SEC website